Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

17 Oct 2014

Abstract excerpt

Somatic mutations (for example, CALR , ASXL1 ) and karyotype have been shown to independently influence survival in patients with myelofibrosis (MF). 1 , 2 The objectives of the current study were to determine if such genetic markers also influence treatment response in MF patients receiving single agent momelotinib and whether such therapy overcomes the detrimental effect of prognostically relevant mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25322686
DOI: 10.1038/leu.2014.306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosisPMID 25322686Read ↗

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.Semantic proximity Read ↗

Momelotinib therapy for myelofibrosis: a 7-year follow-up.Semantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.Semantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.Semantic proximity Read ↗

Impact of molecular profiling on the management of patients with myelofibrosis.Semantic proximity Read ↗

Biological drivers of clinical phenotype in myelofibrosis.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Prognosis of Primary Myelofibrosis in the Genomic Era.Semantic proximity Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.